Samarth Kulkarni

2019

In 2019, Samarth Kulkarni earned a total compensation of $16.3M as Chief Executive Officer at CRISPR Therapeutics AG, a 67% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$438,785
Option Awards$6,495,579
Salary$550,200
Stock Awards$8,775,600
Other$5,568
Total$16,265,732

Kulkarni received $8.8M in stock awards, accounting for 54% of the total pay in 2019.

Kulkarni also received $438.8K in non-equity incentive plan, $6.5M in option awards, $550.2K in salary and $5.6K in other compensation.

Rankings

In 2019, Samarth Kulkarni's compensation ranked 285th out of 13,971 executives tracked by ExecPay. In other words, Kulkarni earned more than 98.0% of executives.

ClassificationRankingPercentile
All
285
out of 13,971
98th
Division
Manufacturing
100
out of 5,695
98th
Major group
Chemicals And Allied Products
28
out of 2,194
99th
Industry group
Drugs
23
out of 1,880
99th
Industry
Biological Products, Except Diagnostic Substances
4
out of 389
99th
Source: SEC filing on April 24, 2020.

Kulkarni's colleagues

We found four more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2019.

2019

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2019

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2019

James Kasinger

CRISPR Therapeutics AG

General Counsel

2019

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

News

You may also like